As an antibody drug, cetuximab, which is a mouse-human (IgG1) chimeric antibody against the epidermal growth factor receptor (EGFR), was approved for the treatment of head and neck cancer (HNC), including oral cancer (1). Here, EGFR is linked to lip and oral cavity carcinoma.